Forget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters Instead

Forget the binary bets of biotech companies, as Royalty Pharma (RPRX) offers a unique opportunity to invest in the royalties generated by blockbuster drugs instead. This dividend stock is an intriguing choice for those seeking a more stable investment in the pharmaceutical sector. Unlike traditional biotech stocks, Royalty Pharma provides capital to drug makers and developers, receiving a royalty on sales generated by the drugs in which it invests.

This way, the investment is less risky, as the company's earnings come from multiple drugs rather than a single drug in development. Over the past years, Royalty Pharma has increased its dividend, demonstrating its commitment to returning value to shareholders. While the yield of 1.5% may not be the highest, it is in line with the average pharmaceutical stock yield of around 1.4%.

The beauty of Royalty Pharma lies in its diversification across the drug sector. With investments in 35 approved products and 16 drugs still in development, the company collects royalties on 16 blockbuster drugs generating sales of $1 billion or more. This spread across different pharmaceutical companies minimizes the risk associated with investing in a single drug or company.

While no company's investments succeed every time, Royalty Pharma's industry expertise and portfolio diversification, along with its management team's success rate, make it a relatively low-risk investment. As the drug sector evolves, Royalty Pharma will continue to adapt its portfolio, making it a potentially attractive long-term investment for those looking to add pharmaceutical exposure to their portfolio.